BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the Fond Unique Interministériel (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma.
This program aims at establishing the proof of concept for the administration by mucosal route of biological products. The first application is a peptide benefiting from the delivery properties of the Lauriad™ mucoadhesive technology. This program will also permit to test the Lauriad™ technology in the veterinary area.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.